Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. - Test2 - elhamkhani - TriplyDB

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

http://www.wikidata.org/entity/Q30500501

about

Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice.Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts Synaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X Syndrome Synaptic Wnt/GSK3β Signaling Hub in Autism Modulation of actin dynamics by Rac1 to target cognitive function Fragile X syndrome and targeted treatment trials.Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background.From FMRP function to potential therapies for fragile X syndrome.Modeling fragile X syndrome in the Fmr1 knockout mouse Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.The clinical implications of mouse models of enhanced anxiety.Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.Sleep, plasticity and the pathophysiology of neurodevelopmental disorders: the potential roles of protein synthesis and other cellular processes.Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Fmr1 Knockout Mouse Model of Fragile X Syndrome.Fragile X mental retardation protein regulates synaptic and behavioral plasticity to repeated cocaine administration Lithium: a promising treatment for fragile X syndrome.Fragile X targeted pharmacotherapy: lessons learned and future directions.Effects of a social stimulus on gene expression in a mouse model of fragile X syndrome Fragile X syndrome: an update on developing treatment modalities.Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome Behavioral and synaptic circuit features in a zebrafish model of fragile X syndrome.PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome A mouse model of the fragile X premutation: effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis.Neuroprotective action of lithium in disorders of the central nervous system.Effects of chronic immobilization stress on anxiety-like behavior and basolateral amygdala morphology in Fmr1 knockout mice.Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells.Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome Targeted treatments for fragile X syndrome.R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.Developmental characteristics of dendritic spines in the dentate gyrus of Fmr1 knockout mice.Behavioral Phenotype of Fmr1 Knock-Out Mice during Active Phase in an Altered Light/Dark Cycle.Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.

P2860

Q21135541-557DA42D-B9F7-4347-8857-FFF7FAD42B2E Q24626017-2F394182-CF78-4F07-9108-300691DE4BA3 Q26741164-0D6B77D0-0279-4B94-B703-69123D3D9693 Q26745117-4CD5BD61-1B78-4543-9A97-2E501A8A3169 Q26765504-C154BE66-5EAE-44C4-86B4-B30DF845B2C9 Q26820813-AEC01CBC-5889-4DD5-A460-4B8AAEA7E6E8 Q26865162-9A855265-2EB0-4390-BE63-BF6DCE231288 Q26866506-7D8DF2FC-5F8E-4A61-8ACC-4DA7316BD461 Q27337360-692D4119-2D4E-491C-8952-03610602D5FC Q28261563-E0BCE0D4-D162-4199-87FD-538EE041C88C Q30403591-2948DF85-D1C8-4160-A8D1-47F7102A6CB8 Q30410502-D4D4F2A2-475F-4E2F-8B1B-B00105B6D2C9 Q30420595-2EF37074-7744-4562-A5DF-089D3FFFDF5E Q30458768-0D744BD6-B852-4928-BFB2-E2BA3FB5F82C Q30461456-263D72EE-34A2-4E1D-BBBD-2CA35DA0CA4A Q30474232-429E3D11-702C-445A-99D8-13D732199F77 Q30572014-B65A1DF9-84A8-4928-850B-B8CD8458957D Q30823493-5B5DEA0F-97AB-4A1F-B06A-B264395CC6EA Q30855390-3C9E7424-9E87-42B6-BBC6-E2C758BC6122 Q33573692-C1282646-F5D5-415D-954E-B9482C3F3ED8 Q33738812-2C055828-80B6-46E0-B994-81EAC5DC4C7E Q33777951-E171983D-5A83-428F-A28F-0140F1D71B2F Q33785983-A162693C-795F-4034-8D27-E1A89DEA55FE Q33827442-EDB1594A-8DE2-46DD-92F0-417E6A61F708 Q34292108-6B439968-AE39-422C-80CE-D68F99A41F24 Q34573192-6A4EAF65-10CF-4308-89C3-401475AB1EC1 Q34638909-9BC53410-44AD-472D-B5E7-6C59D8A4675F Q34869830-D37D0912-7972-49DA-BA4A-E3D7BD0E0726 Q35148962-0681E125-ABBB-4309-B7B9-B8531D6BEDCC Q35212429-C61B2AD0-E07F-46F4-A96A-5D66D0886EF1 Q35243625-F22FC833-43C4-4F78-9CD7-E70B740EEA38 Q35492486-8B907BC9-40DE-432F-A5A9-A2B942C5B17D Q35614072-537E3714-7B10-4971-9292-6681F6C2A0DA Q35638949-5A10DB8B-A0D8-46FE-84E6-094FE350D09D Q35674710-EED1EFFB-014F-4283-9EFA-62A0F3FFB97E Q35680726-CE1CE119-22A5-42DF-A25F-53A7E5F1ECEF Q36077206-053FC697-4B8D-4FDE-A0A0-6E9D7750D42A Q36207550-892E2A44-7BE4-4DFD-8A8D-C6E226763B19 Q36990260-5B25DA3A-7145-4F39-AAE7-2528461FF8FD Q37054398-DE87E8CE-CF32-4CF6-8138-715F981B6C61

P2860

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

http://www.wikidata.org/entity/Q30500501

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

@ast

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

@en

type

label

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

@ast

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

@en

prefLabel

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

@ast

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

@en

P1433

Q30500501-EC92D160-16D1-45DE-A0EF-D3F46012793F

P1476

Q30500501-A9E94C8A-628C-4668-9015-97F3E182E97F

P2093

Q30500501-53297479-FCF6-4A21-9C53-DFC61280C4BA

Q30500501-565EB761-78C9-4BC9-9792-74319964F363

Q30500501-FADF0D7A-36D3-47E1-A6AC-45EEBCE3827A

P2860

Q30500501-02AD4D54-DE33-4A47-B864-A11C02A3A2B1

Q30500501-05BFE7E9-D68C-4A9F-AC53-8A8D9F3B36EA

Q30500501-0CFED9DB-DC6F-4556-AC9A-B0E1F66A78AB

Q30500501-0F13FF0A-B51C-4BE3-A010-B91B9F7D9217

Q30500501-1E85F308-3B7D-4515-8343-4324B53411C8

Q30500501-1FE0F1F1-02C6-4155-9001-84143E913A72

Q30500501-24C9A5D5-CC58-4D1F-823A-38708D1B6315

Q30500501-24D5C4F6-4D6B-4B81-82A7-A10C5D0F2034

Q30500501-2E317EE6-8F35-4393-A2E3-8361CF0A734B

Q30500501-2FF168AE-C002-4130-B06B-2865CF6DC703

P304

Q30500501-CBDF6F73-DAF1-4AA1-9796-C43B1D580736

P31

Q30500501-7E1ED3E2-090D-4E9A-A6D7-5F58F6A67DD2

P356

Q30500501-114D856C-0E58-4BF1-B43B-751B5F53ED45

P433

Q30500501-35B32DB8-767E-499A-A530-F52509D08D4E

P478

Q30500501-BC45F13F-BBFC-452B-AF09-4DDD9ADE82DF

P577

Q30500501-AF95F220-F9F1-4C12-B78E-942456959C6C

P698

Q30500501-14CC35AB-6667-4792-AAEE-0718140201E6

P932

Q30500501-A055BE36-1EBC-484C-880A-AF9BEC1D7D31

P356

S1461145710000520

P1433

The International Journal of Neuropsychopharmacology

P1476

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

@en

P2093

Carolyn Beebe Smith

http://www.w3.org/2001/XMLSchema#string

De-Maw Chuang

http://www.w3.org/2001/XMLSchema#string

Zhong-Hua Liu

http://www.w3.org/2001/XMLSchema#string

P2860

A molecular mechanism for the effect of lithium on development

Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits

Neural and developmental actions of lithium: a unifying hypothesis

Lithium prevention of amphetamine-induced 'manic' excitement and of reserpine-induced 'depression' in mice: possible role of 2-phenylethylamine

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling

Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila.

Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.

Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome.

Social behavior deficits in the Fmr1 mutant mouse.

P304

618-630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S1461145710000520

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20497624

http://www.w3.org/2001/XMLSchema#string

P932

3102293

http://www.w3.org/2001/XMLSchema#string